ELUTHealthcare · Medical DevicesThe 1 Wall Street analysts covering Elutia, Inc. hold a median 12-month price target of $5 — +514.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 28 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Elutia, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (83): Smaller than most of the companies we track.
Accruals (14): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ELUT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +514.6% from it.
Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Sept 2025 | Lake Street | Maintains | Buy | $8.00 → $6.00 |
| 10 Sept 2025 | Lake Street | Maintains | Buy | — |
| 9 May 2025 | Lake Street | Maintains | Buy | — |
| 7 Mar 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 15 Nov 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 6 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 8 Aug 2024 | Cantor Fitzgerald | Maintains | Overweight | — |
| 21 June 2024 | Lake Street | Maintains | Buy | — |
| 20 June 2024 | Cantor Fitzgerald | Maintains | Overweight | — |
| 18 June 2024 | Cantor Fitzgerald | Maintains | Overweight | — |
| 10 May 2024 | Cantor Fitzgerald | Maintains | Overweight | — |
| 14 Nov 2023 | Cantor Fitzgerald | Maintains | Overweight | — |
| 28 Sept 2023 | Lake Street | Initiates | Buy | — |
| 26 Sept 2023 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 19 Sept 2023 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 15 Aug 2023 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 12 May 2023 | Cantor Fitzgerald | Maintains | Overweight | $12 → $10 |
| 16 Nov 2022 | Truist Securities | Maintains | Buy | $8.00 → $10 |
| 15 Nov 2022 | Piper Sandler | Maintains | Overweight | $9.00 → $11 |
| 4 Mar 2022 | Cowen & Co. | Maintains | Outperform | $15 → $13 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ELUT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Elutia, Inc. returned −9.9% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 71% of US stocks
Cheaper than 39% of US stocks
Cheaper than 38% of US stocks
Cheaper than 69% of US stocks
Higher than 15% of US stocks
Higher than 8% of US stocks
Higher than 73% of US stocks
Higher than 10% of US stocks
Higher than 99% of US stocks
Higher than 98% of US stocks
Higher than 12% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Elutia, Inc. has a market value of $37.2M and an enterprise value of $21.7M.
Revenue in the twelve months to 30 June 2026: $12.1M. The latest quarter shrank 11.6% year on year.
Net income over the same four quarters: $51.8M, a 426.9% net margin.
Diluted earnings per share, trailing twelve months: $0.95.
Free cash flow in the twelve months to 30 June 2026: −$46.0M, after $2.0M of capital spending.
Trailing P/E: 0.6×; forward P/E: −0.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Elutia, Inc. employs 25 people — $485K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Elutia, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Elutia announced that it will release its third-quarter 2026 financial results after market close on Thursday, November 5, 2026.
Why it matters — ELUT watchers may note the scheduled date for the company’s quarterly financial results.
Elutia announced it has received the full $8 million held in escrow from Boston Scientific in connection with the sale of its BioEnvelope business, released on schedule with no claims. This escrow release marks the third funding catalyst for Elutia in 2026, following its Avenue Capital loan facility and the SimpliDerm divestiture, leaving the company fully funded into 2029 and through the first year of the expected NXT-41x launch.
Why it matters — The escrow release provides additional capital that fully funds Elutia into 2029, removing near-term funding pressure as it prepares for the expected NXT-41x launch.
Elutia announced that its CEO, Chief Scientific Officer, and CFO will present and host one-on-one meetings with investors at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th. The company described itself as a pioneer in drug-eluting biomatrix technologies.
Why it matters — The conference appearance gives ELUT watchers an opportunity to hear directly from the company's leadership about its drug-eluting biomatrix technologies and engage with top executives.
Elutia announced that its CEO Dr. Randy Mills, CFO Matthew Ferguson, and CSO Dr. Michelle Williams will participate in two upcoming investor conferences: the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference and the H.C. Wainwright 28th Annual Global Investment Conference.
Why it matters — An ELUT watcher would care because Elutia's leadership team is scheduled to present at these investor conferences, raising the company's visibility among institutional investors.
Cellution Biologics announced it has completed its acquisition of the SimpliDerm hydrated human acellular dermal matrix (ADM) business from Elutia Inc. The transaction was announced in a GlobeNewsWire release dated August 18, 2026.
Why it matters — The completion of this divestiture marks a structural change in Elutia's business, as it has transferred ownership of its SimpliDerm ADM product line to Cellution Biologics.
The 1 Wall Street analysts covering Elutia, Inc. have a median 12-month price target of $5, with estimates ranging from $5 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Elutia, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Elutia, Inc. 37 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Elutia, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (83 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +514.6% from the last close, and Ticker Nerd's factor model ranks Elutia, Inc. 37 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Elutia, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELUT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $5 over the next 12 months.
Elutia, Inc. returned -9.9% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Elutia Inc. is a commercial-stage biomedical company focused on drug-eluting biomatrix products used in surgical reconstruction and related medical applications.
The most recent item we track (GlobeNewsWire, 22 Oct 2026): "Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026". Elutia announced that it will release its third-quarter 2026 financial results after market close on Thursday, November 5, 2026.
Elutia Inc. is a commercial-stage biomedical company focused on drug-eluting biomatrix products used in surgical reconstruction and related medical applications. Elutia’s products are designed to improve how implantable medical devices and surrounding tissue interact, with use cases in areas such as device protection, women’s health, and cardiovascular care. The company offers biologic solutions intended for procedures involving implanted electronic devices, soft tissue repair, and regenerative support. Its portfolio serves healthcare providers working across specialized surgical settings where compatibility, tissue integration, and complication reduction are important. Elutia Inc. operates as a focused player in the regenerative medicine and biomaterials market, addressing needs in implant-based procedures and reconstructive care.
CEO Dr. C. Randal Mills Ph.D. · 25 employees · United States · https://elutia.com
